安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Aprepitant Uses, Side Effects Warnings - Drugs. com
What is aprepitant? Aprepitant is used together with other medications to prevent nausea and vomiting that may be caused by chemotherapy Aprepitant may also be used in adults to prevent nausea and vomiting after surgery Aprepitant is not used to treat nausea and vomiting that you already have
- Aprepitant - Wikipedia
Aprepitant is classified as an NK 1 antagonist because it blocks signals given off by NK 1 receptors This, therefore, decreases the likelihood of vomiting in patients
- Aprepitant (oral route) - Side effects dosage - Mayo Clinic
Aprepitant capsules and oral suspension are used in combination with other medicines to prevent the nausea and vomiting that may occur during cancer treatment (chemotherapy)
- Aprepitant (Emend oral, Cinvanti, Aponvie): Uses, Side Effects . . . - WebMD
Aprepitant is a type of medicine known as an antiemetic (anti-nausea medicine) It works by preventing a substance in the brain from binding to neurokinin-1 (NK1) receptors
- Aprepitant - StatPearls - NCBI Bookshelf
Aprepitant is a medication used to manage and treat chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV) It is in the neurokinin-1 antagonist class of medications
- Aprepitant Capsules - Cleveland Clinic
Aprepitant Capsules What is this medication? APREPITANT (ap RE pi tant) prevents nausea and vomiting from chemotherapy It works by blocking substances in your body that may cause nausea and vomiting It belongs to a class of medications called antiemetics
- Aprepitant: Package Insert Prescribing Information - Drugs. com
Aprepitant package insert prescribing information for healthcare professionals Includes: indications, dosage, adverse reactions and pharmacology
- Aprepitant: Uses, Interactions, Mechanism of Action | DrugBank Online
Aprepitant, an antiemetic, is a substance P neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
|
|
|